Full-Time

Senior Director – Early Differentiation and Pipeline Lead

WW Medical

Confirmed live in the last 24 hours

Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

No salary listed

Senior, Expert

Company Historically Provides H1B Sponsorship

Princeton, NJ, USA

50% Flexible Work Arrangement onsite in NJ (Princeton Pike or Madison, NJ)

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Advanced degree preferred (MD, PharmD, PhD)
  • 8-10 years clinical, medical, or other pharma industry experience
  • A breadth of relevant industry experience (Discovery, Medical Affairs or Clinical Development, Commercial)
  • Candidate should ideally have experience developing Medical plans / ISR/IST strategy
  • Candidate should ideally have therapeutic experience in Immunology and/or Neurology and/or Cardiovascular
  • Candidate should ideally have experience interfacing & influencing executive leadership
  • Candidate should ideally have experience interfacing with translational medicine /diagnostics
  • Experience in a customer-facing role with thought leaders and key customers in the early clinical space preferred
Responsibilities
  • Develop and execute medical differentiation plans for assigned compounds across 4 domains: 1) Insight gathering and integration; 2) Evidence generation; 3) Medical Communications; 4) Patient Journey
  • Be a critical partner to Early Asset Development Program Leads, Clinical Development Leads, ICN Medical/Commercial teams, and Translational Medicine to ensure medical readiness and to deliver against objectives and program milestones, as a core member of the early GPTs
  • Serve as a primary source of Medical accountability for a set of early assets; matrix management responsibilities across the internal network (Commercial, R&D, Medical, & Access)
  • Ensure the development of a clearly differentiated TPP for each early asset
  • Own the Integrated Evidence Plans (IEP) to complement data generation with Early Drug Development & ongoing evaluation of IST/ITT/strategic collaboration proposals, including medical biomarker and TM components
  • Develop innovative Early Asset internal and external medical education presentations, programs, and training
  • Partner with external Thought Leaders (on ongoing basis) to gain medical advice on Early Asset compound strategies, with a goal to inform asset decision making and portfolio tradeoffs
  • Be the voice of Medical to inform and accelerate decision making and governance for assigned compounds
  • Support asset / study level objectives (protocol development, study start-up, enrollment & engagement)
  • Work with publications and colleagues from across the business to develop and execute a robust publication strategy
  • Partner with the Translational Medicine & Diagnostic and Commercial on precision medicine strategy for ICN
  • Exercise enterprise mindset with ability to work in highly matrixed environment
  • Be a science-driven Medical Affairs professional with high business acumen
Desired Qualifications
  • 50% Flexible Work Arrangement onsite in NJ (Princeton Pike or Madison, NJ)

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, as well as its commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) principles.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery accelerates BMS's R&D, improving drug development efficiency.
  • BMS's acquisition of 2seventy bio enhances its cancer cell therapy capabilities.
  • Positive Phase 3 trial results for Sotyktu boost BMS's psoriatic arthritis treatment portfolio.

What critics are saying

  • Increased competition in oncology may impact BMS's market share.
  • Layoffs could decrease employee morale, affecting operational efficiency.
  • Integration challenges from acquiring 2seventy bio may pose financial risks.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases, setting it apart in biopharma.
  • The company integrates AI in early lung cancer diagnosis, enhancing precision care.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

European HHHM
Apr 16th, 2025
Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis

Optellum, a global leader in AI-driven clinical decision support for early lung cancer diagnosis, has entered an agreement with Bristol Myers Squibb (NYSE: BMY), to leverage AI in early diagnosis and precision lung cancer care.

CMMB
Mar 24th, 2025
Our Values, Your Impact

In partnership with Bristol Myers Squibb, Catholic Medical Mission Board Inc. is playing a role in building the infrastructure and workforce to bring quality cancer care to rural Kenya.

PR Newswire
Mar 20th, 2025
Bristol Myers Squibb Appoints Osama Braiwish As General Manager For Saudi Arabia Gulf Countries

RIYADH, Saudi Arabia, March 20, 2025 /PRNewswire/ -- Bristol Myers Squibb, a leading global biopharmaceutical company, has recently appointed Osama Braiwish as its General Manager for Saudi Arabia and Gulf Countries, an affiliate covering Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, and Jordan

Investors Hangout
Mar 20th, 2025
Bristol Myers Squibb Welcomes New Leadership in Gulf Region

Bristol Myers Squibb, a leader in the global biopharmaceutical sector, has appointed Osama Braiwish as its General Manager for the Gulf region, thereby enhancing its capacity to serve medical needs across various specialties.

Business Wire
Mar 12th, 2025
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all